These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 25707911)
1. Stereotactic body radiotherapy for prostate cancer. Henderson DR; Tree AC; van As NJ Clin Oncol (R Coll Radiol); 2015 May; 27(5):270-9. PubMed ID: 25707911 [TBL] [Abstract][Full Text] [Related]
2. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626 [TBL] [Abstract][Full Text] [Related]
3. Continuous monitoring and intrafraction target position correction during treatment improves target coverage for patients undergoing SBRT prostate therapy. Lovelock DM; Messineo AP; Cox BW; Kollmeier MA; Zelefsky MJ Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):588-94. PubMed ID: 25680601 [TBL] [Abstract][Full Text] [Related]
4. Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Hossain S; Xia P; Chuang C; Verhey L; Gottschalk AR; Mu G; Ma L Med Phys; 2008 Sep; 35(9):4041-8. PubMed ID: 18841856 [TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy in prostate cancer: is rapidarc a better solution than cyberknife? Macdougall ND; Dean C; Muirhead R Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):4-9. PubMed ID: 24071450 [TBL] [Abstract][Full Text] [Related]
6. Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction. Musunuru HB; Loblaw A Future Oncol; 2015; 11(5):819-31. PubMed ID: 25757684 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. King CR; Brooks JD; Gill H; Presti JC Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):877-82. PubMed ID: 21300474 [TBL] [Abstract][Full Text] [Related]
8. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Arcangeli S; Scorsetti M; Alongi F Crit Rev Oncol Hematol; 2012 Oct; 84(1):101-8. PubMed ID: 22257653 [TBL] [Abstract][Full Text] [Related]
9. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Berkovic P; De Meerleer G; Delrue L; Lambert B; Fonteyne V; Lumen N; Decaestecker K; Villeirs G; Vuye P; Ost P Clin Genitourin Cancer; 2013 Mar; 11(1):27-32. PubMed ID: 23010414 [TBL] [Abstract][Full Text] [Related]
10. The Technique, Resources and Costs of Stereotactic Body Radiotherapy of Prostate Cancer: A Comparison of Dose Regimens and Delivery Systems. Sharieff W; Greenspoon JN; Dayes I; Chow T; Wright J; Lukka H Technol Cancer Res Treat; 2016 Feb; 15(1):171-8. PubMed ID: 24750007 [TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy for prostate cancer. Ishiyama H; Teh BS; Lo SS; Mathews T; Blanco A; Amato R; Ellis RJ; Mayr NA; Paulino AC; Xu B; Butler BE Future Oncol; 2011 Sep; 7(9):1077-86. PubMed ID: 21919695 [TBL] [Abstract][Full Text] [Related]
12. Prostate stereotactic body radiotherapy—first UK experience. Tree AC; Ostler P; Hoskin P; Dankulchai P; Nariyangadu P; Hughes RJ; Wells E; Taylor H; Khoo VS; van As NJ Clin Oncol (R Coll Radiol); 2014 Dec; 26(12):757-61. PubMed ID: 25193299 [TBL] [Abstract][Full Text] [Related]
13. [Hypofractionated radiotherapy in prostate cancer]. Supiot S; Créhange G; Latorzeff I; Pommier P; Paumier A; Rio E; Delaroche G; Guérif S; Catton C; Martin J; Lisbona A Cancer Radiother; 2013 Oct; 17(5-6):349-54. PubMed ID: 23973460 [TBL] [Abstract][Full Text] [Related]
15. TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol. Martin J; Keall P; Siva S; Greer P; Christie D; Moore K; Dowling J; Pryor D; Chong P; McLeod N; Raman A; Lynam J; Smart J; Oldmeadow C; Tang CI; Murphy DG; Millar J; Tai KH; Holloway L; Reeves P; Hayden A; Lim T; Holt T; Sidhom M BMJ Open; 2019 Aug; 9(8):e030731. PubMed ID: 31434782 [TBL] [Abstract][Full Text] [Related]
16. Pushing the limits of radiation therapy for prostate cancer: where do we go next? Mishra MV; Showalter TN Semin Oncol; 2013 Jun; 40(3):297-307. PubMed ID: 23806495 [TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555 [TBL] [Abstract][Full Text] [Related]
18. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135 [TBL] [Abstract][Full Text] [Related]
19. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study. Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594 [TBL] [Abstract][Full Text] [Related]